الصفحة الرئيسية>>Signaling Pathways>> Ubiquitination/ Proteasome>> Autophagy>>10058-F4

10058-F4

رقم الكتالوجGC17295

10058-F4 هو مثبط c-Myc الذي يمنع ثنائيات c-Myc-Max ومعاملات التعبير الجيني المستهدف لـ c-Myc

Products are for research use only. Not for human use. We do not sell to patients.

10058-F4 التركيب الكيميائي

Cas No.: 403811-55-2

الحجم السعر المخزون الكميّة
10mM (in 1mL DMSO)
37٫00
متوفر
5mg
31٫00
متوفر
10mg
53٫00
متوفر
50mg
159٫00
متوفر

Tel:(909) 407-4943 Email: sales@glpbio.com


مراجعات العميل

بناء على آراء العملاء.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description of 10058-F4

10058-F4 is a c-Myc inhibitor that inhibits c-Myc-Max dimerization and prevents transcriptional activation of c-Myc target gene expression[1]. 10058-F4 can promote caspase-3-dependent apoptosis and regulate autophagy[2]. 10058-F4 has anti-leukemia effects[3].

In vitro, 10058-F4 (0-200µM) treatment of ovarian cancer cell lines (SKOV3 and Hey cells) for 72h inhibited the proliferation of both cell lines in a dose-dependent manner, with IC50 values of 4.4µM and 3.2µML for SKOV3 and Hey cells, respectively, induced cell cycle arrest and apoptosis, and reduced reactive oxygen species (ROS) and ATP generation[4]. 10058-F4 (60μM) treatment of NALM6 and CEM cells for 24h significantly enhanced dexamethasone (DXM)-induced cell growth inhibition, G0/G1 phase arrest and apoptosis[5]. 10058-F4 (0-150μM) treatment of leukemia cells (HL-60, U937 and NB4 cells) for 72h inhibited the proliferation of all three cell types in a dose-dependent manner, induced cell cycle arrest and apoptosis, and myeloid differentiation[6].

In vivo, 10058-F4 (25mg/kg/day) was administered intraperitoneally to mice with acute colitis, which weakened the LiCl-induced colon regeneration effect and reduced the expression of Ccnd2 and Cad[7]. 10058-F4 (15mg/kg) was administered intraperitoneally to mice with PANC-1 cell xenografts for 30 days, 10058-F4 alone had no significant effect on tumorigenesis, but when used in combination with gemcitabine, it significantly attenuated tumorigenesis and reduced PCNA-positive cells and TUNEL-positive cells[8].

References:
[1] Lin C P, Liu J D, Chow J M, et al. Small-molecule c-Myc inhibitor, 10058-F4, inhibits proliferation, downregulates human telomerase reverse transcriptase and enhances chemosensitivity in human hepatocellular carcinoma cells[J]. Anti-cancer drugs, 2007, 18(2): 161-170.
[2] Sheikh‐Zeineddini N, Bashash D, Safaroghli‐Azar A, et al. Suppression of c‐Myc using 10058‐F4 exerts caspase‐3‐dependent apoptosis and intensifies the antileukemic effect of vincristine in pre‐B acute lymphoblastic leukemia cells[J]. Journal of cellular biochemistry, 2019, 120(8): 14004-14016.
[3] Zehtabcheh S, Sheikh‐Zeineddini N, Yousefi A M, et al. Anti-Leukemic Effects of Small Molecule Inhibitor of c-Myc (10058-F4) on Chronic Myeloid Leukemia Cells[J]. Asian Pacific Journal of Cancer Prevention, 2024, 25(6): 1959-1967.
[4] Wang J, Ma X, Jones H M, et al. Evaluation of the antitumor effects of c-Myc-Max heterodimerization inhibitor 100258-F4 in ovarian cancer cells[J]. Journal of translational medicine, 2014, 12: 1-11.
[5] Lv M, Wang Y, Wu W, et al. CMyc inhibitor 10058F4 increases the efficacy of dexamethasone on acute lymphoblastic leukaemia cells[J]. Molecular Medicine Reports, 2018, 18(1): 421-428.
[6] Huang M J, Cheng Y, Liu C R, et al. A small-molecule c-Myc inhibitor, 10058-F4, induces cell-cycle arrest, apoptosis, and myeloid differentiation of human acute myeloid leukemia[J]. Experimental hematology, 2006, 34(11): 1480-1489.
[7] Raup-Konsavage W M, Cooper T K, Yochum G S. A role for MYC in lithium-stimulated repair of the colonic epithelium after DSS-induced damage in mice[J]. Digestive diseases and sciences, 2016, 61: 410-422.
[8] Zhang M, Fan H Y, Li S C. Inhibition of c-Myc by 10058-F4 induces growth arrest and chemosensitivity in pancreatic ductal adenocarcinoma[J]. Biomedicine & pharmacotherapy, 2015, 73: 123-128.

Protocol of 10058-F4

Cell experiment [1]:

Cell lines

SKOV3、Hey cells

Preparation Method

SKOV3 and Hey cells were cultured for 24h and treated with 0-200µM 10058-F4 for 72h. Cell proliferation was assessed using the MTT assay.

Reaction Conditions

0-200µM; 72h

Applications

10058-F4 inhibited the growth of both cell lines in a concentration-dependent manner, with IC50 values of 4.4µM for SKOV3 cells and 3.2µM for Hey cells.

Animal experiment [2]:

Animal models

C57BL/ 6 mice

Preparation Method

Colitis was induced in 7-week-old male and female C57BL/ 6 mice by administering 2.5 % DSS in their drinking water for five days. Following DSS treatment, the animals were returned to normal drinking water and allowed to recover for up to four days. For lithium treatments, animals received a single 200µL intraperitoneal injection of 4mg LiCl. For experiments involving MYC inhibition, animals were given 25mg/kg 10058-F4 intraperitoneal injection daily. At each day during recovery, mice were weighed and disease activity index (DAI) scores were assessed. Colonic tissue samples were also collected during each day of the recovery period, fixed in formaldehyde and paraffin-em bedded or stored in a -80 C freezer until analysis.

Dosage form

25mg/kg/day; i.p.

Applications

10058-F4 inhibited c-MYC transcription factor (MYC) function in lithium-treated mice, reducing the beneficial effects of lithium treatment. Mice that received 10058-F4 alone had severe damage to the colonic epithelium, accompanied by widespread inflammation.

References:

[1]Wang J, Ma X, Jones H M, et al. Evaluation of the antitumor effects of c-Myc-Max heterodimerization inhibitor 100258-F4 in ovarian cancer cells[J]. Journal of translational medicine, 2014, 12: 1-11.

[2]Raup-Konsavage W M, Cooper T K, Yochum G S. A role for MYC in lithium-stimulated repair of the colonic epithelium after DSS-induced damage in mice[J]. Digestive diseases and sciences, 2016, 61: 410-422.

Chemical Properties of 10058-F4

Cas No. 403811-55-2 SDF
Chemical Name (5E)-5-[(4-ethylphenyl)methylidene]-2-sulfanylidene-1,3-thiazolidin-4-one
Canonical SMILES CCC1=CC=C(C=C1)C=C2C(=O)NC(=S)S2
Formula C12H11NOS2 M.Wt 249.35
الذوبان ≥ 24.9mg/mL in DMSO Storage Store at -20°C
General tips Please select the appropriate solvent to prepare the stock solution according to the solubility of the product in different solvents; once the solution is prepared, please store it in separate packages to avoid product failure caused by repeated freezing and thawing.Storage method and period of the stock solution: When stored at -80°C, please use it within 6 months; when stored at -20°C, please use it within 1 month.
To increase solubility, heat the tube to 37°C and then oscillate in an ultrasonic bath for some time.
Shipping Condition Evaluation sample solution: shipped with blue ice. All other sizes available: with RT, or with Blue Ice upon request.

Complete Stock Solution Preparation Table of 10058-F4

Prepare stock solution
1 mg 5 mg 10 mg
1 mM 4.0104 mL 20.0521 mL 40.1043 mL
5 mM 0.8021 mL 4.0104 mL 8.0209 mL
10 mM 0.401 mL 2.0052 mL 4.0104 mL
  • حاسبة المولارية

  • حاسبة التخفيف

  • Molecular Weight Calculator

كتلة
=
تركيز
x
مقدار
x
ميغاواط *
 
 
 
** عند إعداد حلول المخزون، دائمًا استخدم الوزن الجزيئي الخاص بالدفعة للمنتج على ملصق القارورة MSDS / CoA (متوفر عبر الإنترنت).

احسب

In vivo Formulation Calculator (Clear solution) of 10058-F4

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

mg/kg g μL

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO % % Tween 80 % ddH2O
%DMSO %

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.
3. All of the above co-solvents are available for purchase on the GlpBio website.

Product Documents

Quality Control & SDS

View current batch:

مراجعات

Review for 10058-F4

Average Rating: 5 ★★★★★ (Based on Reviews and 9 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for 10058-F4

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.